Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018)

References

• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410.
   PubMed Web of Science ®Google Scholar
• Taddei ML, Giannoni E, Comito G, et al. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013;341:80–96.
   PubMed Web of Science ®Google Scholar
• Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010;29:285–293.
   PubMed Web of Science ®Google Scholar
• Lendahl U, Lee KL, Yang H, et al. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet. 2009;10:821–832.
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–899.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Axelson H, Fredlund E, Ovenberger M, et al. Hypoxia-induced dedifferentiation of tumor cells – a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol. 2005;16:554–563.
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol. 2015;31:52–64.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum JY, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84–97.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 2018. in press. DOI:10.1002/med.21497.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:48.
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat. 2013;23:737–749.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms. Chem Rev. 2012;112:4421–4468.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877–2888.
   PubMed Web of Science ®Google Scholar
• Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol. 2011;99:424–431.
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA. 1998;95:7608–7613.
   PubMed Web of Science ®Google Scholar
• Karhumaa P, Parkkila S, Tureci O, et al. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum Reprod. 2000;6:68–74.
   PubMed Web of Science ®Google Scholar
• Parkkila S, Parkkila AK, Saarnio J, et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem. 2000;48:1601–1608.
   PubMed Web of Science ®Google Scholar
• Liao SY, Ivanov S, Ivanova A, et al. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J Med Genet. 2003;40:257–261.
   PubMed Web of Science ®Google Scholar
• Haapasalo J, Hilvo M, Nordfors K, et al. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol. 2008;10:131–138.
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Chen KS, Chiou HL, et al. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signalling pathway. Eur J Cell Biol. 2010;89:598–606.
   PubMed Web of Science ®Google Scholar
• Kivela AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol. 2000;114:197–204.
   PubMed Web of Science ®Google Scholar
• Kivela A, Parkkila S, Saarnio J, et al. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol. 2000;156:577–584.
   PubMed Web of Science ®Google Scholar
• Kivela AJ, Parkkila S, Saarnio J, et al. Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J Gastroenterol. 2005;11:2616–2625.
   PubMed Web of Science ®Google Scholar
• Ilie MI, Hofman V, Ortholan C, et al. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer. 2011;128:1614–1623.
   PubMed Web of Science ®Google Scholar
• Wingo T, Tu C, Laipis PJ, et al. The catalytic properties of human carbonic anhydrase IX. Biochem Biophys Res Commun. 2001;288:666–669.
   PubMed Web of Science ®Google Scholar
• Liao SY, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997;57:2827–2831.
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A. 2009;106:16233–16238.
   PubMed Web of Science ®Google Scholar
• Leitans J, Kazaks A, Balode A, et al. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem. 2015;58:9004–9009.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Bhatt A, Socorro L, et al. The structure of carbonic anhydrase IX is adapted for low-pH catalysis. Biochemistry. 2016;55:4642–4653.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta. 2010;1804:404–409.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA. 2001;98:9545–9550.
   PubMed Web of Science ®Google Scholar
• Svastova E, Zilka N, Zatovicova M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res. 2003;290:332–345.
   PubMed Web of Science ®Google Scholar
• Zavadova Z, Zavada J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol Rep. 2005;13:977–982.
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 2000;82:1808–1813.
   PubMed Web of Science ®Google Scholar
• Ditte P, Dequiedt F, Svastova E, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res. 2011;71:7558–7567.
   PubMed Web of Science ®Google Scholar
• Dorai T, Sawczuk IS, Pastorek J, et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer. 2005;41:2935–2947.
   PubMed Web of Science ®Google Scholar
• Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem. 2008;283:27799–27809.
   PubMed Web of Science ®Google Scholar
• Buanne P, Renzone G, Monteleone F, et al. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. J Proteome Res. 2013;12:282–292.
   PubMed Web of Science ®Google Scholar
• Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett. 2005;15:963–969.
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69:358–368.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Matsumoto T, Ryuge S, et al. CAXII is a sero-diagnostic marker for lung cancer. PLoS One. 2012;7:e33952.
   PubMed Web of Science ®Google Scholar
• Yoo CW, Nam BH, Kim JY, et al. Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiat Oncol Lond Engl. 2010;5:101.
   PubMed Web of Science ®Google Scholar
• Kopecka J, Campia I, Jacobs A, et al. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget. 2015;6:6776–6793.
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renalcell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489–494.
   PubMed Web of Science ®Google Scholar
• Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol. 2011;29:121–126.
   PubMed Web of Science ®Google Scholar
• Wilex Ariser, adjuvant RENCAREX immunotherapy phase III trial to study efficacy in non metastatic RCC. [ cited 2018 May 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT00087022.
   Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 2010;16:3255–3263.
   PubMed Web of Science ®Google Scholar
• Murri-Plesko MT, Hulikova A, Oosterwijk E, et al. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol. 2011;657:173–183.
   PubMed Web of Science ®Google Scholar
• Marasco WA, Lo A, Xu C Carbonic anhydrase IX (G250) antibodies and methods of use thereof. US2013336923. 2013.
   Google Scholar
• Marasco W Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof. WO2016100980. 2016.
   Google Scholar
• Lenferink AEG, O’ConnoR M, Marcil A, et al. Carbonic anhydrase IX-specific antibodies and uses thereof. WO2016199097. 2016.
   Google Scholar
• Zeidler R, Battke C, Kremmer E, et al. Novel antibody to a carbonic anhydrase. AU2011250022. 2013.
   Google Scholar
• Moon YR, Ji GY Antibody binding to carbonic anhydrase and use thereof. CA2948743. 2017
   Google Scholar
• Pinard MA, Mahon B, McKenna R. Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors. BioMed Res Int. 2015;2015:453543.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist. J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2012;27:759–772.
   PubMed Web of Science ®Google Scholar
• Ivanova J, Leitans J, Tanc M, et al. X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors. Chem Commun. 2015;51:7108–7111.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Insights towards sulphonamide drug specificity in α-carbonic anhydrases. Bioorg Med Chem. 2013;21:1526–1533.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Barathova M, Kopacek J, et al. Carbonic anhydrase inhibitors targeting cancer: therapeutic, immunologic, and diagnostic tools targeting isoforms IX and XII. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken, New Jersey: Wiley; 2009. p. 193–222.
   Google Scholar
• Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem. 2014;6:1149–1165.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Winum JY, Supuran CT. Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2015;30:321–324.
   PubMed Web of Science ®Google Scholar
• Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2003;13:1005–1009.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Bua S, Lomelino CL, et al. Discovery of new sulfonamide carbonic anhydrase ix inhibitors incorporating nitrogenous bases. ACS Med Chem Lett. 2017;8:1314–1319.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Vullo D, Bartolucci G, et al. N-nitrosulfonamides: A new chemotype for carbonic anhydrase inhibition. Bioorg Med Chem. 2016;24:3612–3617.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lau J, Zhang C, et al. Design, synthesis and evaluation of 18F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. J Enzyme Inhib Med Chem. 2017;32:722–730.
   PubMed Web of Science ®Google Scholar
• Ibrahim HS, Allam HA, Mahmoud WR, et al. Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: selective inhibitors for the tumor-associated hCA IX isoform. Eur J Med Chem. 2018;152:1–9.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem. 1999;42:2641–2650.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Ferraroni M, Nuti E, et al. Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies. Bioorg Med Chem. 2014;22:334–340.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Benedini F, Biondi S, et al. Nitrate esters of carbonic anhydrase inhibitors. WO2008071421. 2008.
   Google Scholar
• Brynda J, Cigler P, Gruner B, et al. Carbonic anhydrase inhibitors and method of their production. US2014303390. 2014
   Google Scholar
• Lambin P, Winum JY, Supuran CT. Cancer targeting using carbonic anhydrase isoform IX inhibitors. WO087115; 2012
   Google Scholar
• Zimmerman C, Babich JW, Joyal J, et al. Inhibitors of carbonic anhydrase IX. WO2009089383. 2009.
   Google Scholar
• Babic J, Zimmerman C, Joyal J, et al. Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX. US2016009664. 2016.
   Google Scholar
• Supuran CT, Scozzafava A Sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents. US2008138291. 2008.
   Google Scholar
• Supuran CT, Scozzafava A, Pastorekova S. CA IX-specific inhibitors. US2008095707. 2008.
   Google Scholar
• Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. AU2012211499. 2012.
   Google Scholar
• Perut F, Carta F, Bonuccelli G, et al. Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment. Expert Opin Ther Targets. 2015;19:1593–1605.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb). 2010;46:8371–8373.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Supuran C, Dedhar S, McDonald P, et al. Novel sulfonamide compounds for inhibition of metastatic tumor growth. WO2012021963. 2012
   Google Scholar
• Safety study of SLC–0111 in subjects with advanced solid tumours. [ cited 2018 May 10]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02215850?term=SLC_0111&rank=1
   Google Scholar
• Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. US2013053392. 2013.
   Google Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55:5591–5600.
   PubMed Web of Science ®Google Scholar
• Zhang Z Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use. WO2017004543. 2017.
   Google Scholar
• Honglin L, Yufang X, Zhenjiang Z, et al. Benzenesulfonamide compound and application thereof. CN102702109. 2012.
   Google Scholar
• LowP LP. Carbonic anhydrase IX targeting agents and methods. WO2017161170. 2017.
   Google Scholar
• Leamon C, Vlahov I, Shillingford J, et al. Carbonic anhydrase ix inhibitor conjugates and uses thereof. WO2017161144. 2017.
   Google Scholar
• Jia L, Cao B Sulfonamides compound of target carbonic anhydrase IX and intermediate as well as preparation and application thereof. CN106278963. 2017.
   Google Scholar
• Krall N, Decurtins W, Neri D, et al. Small molecule drug conjugates. US2017035892. 2017.
   Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 2014;53:4231–4235.
   PubMed Web of Science ®Google Scholar
• Marks IS, Gardeen SS, Kurdziel SJ, et al. Development of a small molecule tubulysin b conjugate for treatment of carbonic anhydrase ix receptor expressing cancers. Mol Pharm. forthcoming. DOI:10.1021/acs.molpharmaceut.8b00139.
   Google Scholar
• Haaga J, Haaga R Targeted treatment of anerobic cancer. US2017056350. 2017.
   Google Scholar
• Haaga J, Haaga R Targeted treatment of anerobic cancer. US20160279084. 2017.
   Google Scholar
• Supuran C, Scozzafava A, Masini E, et al. Carbonic anhydrase inhibitor comprising a dithiocarbamate. WO2013050426. 2013.
   Google Scholar
• Supuran C, Dedhar S, Carta F, et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO2012070024. 2012
   Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131:3057–3062.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Carta F, Ceruso M, et al. Click-tailed coumarins with potent and selective inhibitory action against the tumor-associated carbonic anhydrases IX and XII. Bioorg Med Chem. 2015;23:6955–6966.
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Carta F, Scozzafava A, et al. Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins. J Med Chem. 2016;59:462–473.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71:3364–3376.
   PubMed Web of Science ®Google Scholar
• Bua S, Di Cesare Mannelli L, Vullo D. Design and synthesis of novel nonsteroidal anti-ınflammatory drugs and carbonic anhydrase ınhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem. 2017;60:1159–1170.
   PubMed Web of Science ®Google Scholar
• Akgul O, Di Cesare Mannelli L, Vullo D, et al. Discovery of novel nonsteroidal anti-ınflammatory drugs and carbonic anhydrase ınhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis. J Med Chem. 2018. in press. DOI:10.1021/acs.jmedchem.8b00420.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Parkkila S Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. WO2010139678. 2010
   Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8:E25.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites. 2017;8:E2.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:E48.
   PubMed Web of Science ®Google Scholar